Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
ONDANSETRON HYDROCHLORIDE DIHYDRATE
B. Braun Melsungen AG
ONDANSETRON HYDROCHLORIDE DIHYDRATE
2 Mg/Ml
Solution for Injection
Product subject to prescription which may not be renewed (A)
Withdrawn
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ondansetron 2 mg/ml solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection contains: Ondansetron hydrochloride dihydrate equivalent to 2 mg ondansetron. Each ampoule with 2 ml contains 4 mg ondansetron. Each ampoule with 4 ml contains 8 mg ondansetron. 1 ml solution for injection contains 3.34 mg of sodium as sodium citrate dihydrate and sodium chloride. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection A clear colourless solution in a clear glass ampoule (Type I) containing either 2ml or 4ml of solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting (PONV). _Paediatric Population:_ Ondansetron is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥ 6 months, and for the prevention and treatment of PONV in children aged ≥1 month. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For intravenous injection or for intravenous infusion after dilution. For instructions on dilution of the product before administration, see section 6.6. Prescribers intending to use ondansetron in the prevention of delayed nausea and vomiting associated with chemotherapy or radiotherapy in adults, adolescents or children should take into consideration current practice and appropriate guidelines. Chemotherapy and radiotherapy induced nausea and vomiting _Adults_ The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The Lue koko asiakirja